Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
Executive Summary
A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB
You may also be interested in...
At PSA, Meet The New Deal-Makers (Part 1)
Two of the biopharma industry's newest heads of business development talked with Elsevier Business Intelligence Editor-in-Chief Chris Morrison at the Pharmaceutical Strategic Alliances conference on Sept. 22 in New York.
India's Open Source Drug Discovery Initiative Compiles The TB Genome; Calls For Stronger Global Partnerships For Leads
MUMBAI - A decade after the mycobacterium tuberculosis genome sequence was deciphered, the Indian government's ambitious Open Source Drug Discovery initiative released what is claimed to be the first-ever comprehensive compilation of the mapped TB genome. The collated data will be made available through an open public portal for further analysis, leads and research collaborations
Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore